Key Metrics

Market Cap
Total Shares Outstanding
Book Value
PE Ratio

PS Ratio
PB Ratio
Forward PE Ratio
ROIC

Return on Aseets
Return on Equity
Dividend
Dividend Yield

Balancesheet Metrics

Total Assets
Total Liability
Assets-to-Libability Ratio

Total Current Assets
Total Current Liability
Current Ratio

Quick Ratio
Debt to Equity Ratio

Income Statement Metrics

Net Income
EPS
EBITA

Gross Profit
Gross Profit Margin
Operating Margin

Net Profit Margin

Price Metrics

5 Days MA
10 Days MA
20 Days MA
50 Days MA
200 Days MA

52 Weeks High
52 Weeks low
All Time High

RSI
MACD

Share Stats

Shares Float
Shares Short

% Short
% Insider

% Institutions

% Institutions

News

These Cathie Wood Stocks Are On Sale NowIn this article, we will discuss Cathie Wood stocks that are on sale now. If you want to explore similar stocks, you can also take a look at 5 Cathie Wood Stocks that are on Sale Now. ARK Investment Management's founder and CEO, Cathie Wood, has been recognized as one of the most influential invest...
In this article, we will discuss Cathie Wood stocks that are on sale now. If you want to explore similar stocks, you can also take a look at 5 Cathie Wood Stocks that are on Sale Now. ARK Investment Management's founder and CEO, Cathie Wood, has been recognized as one of the most influential investors in the world owing to her stock-picking prowess that often generate above-average market returns over the long term. Founded in 2014, Ark Innovation ETF (ARKK) is her flagship fund that elicits strong interest and following on Wall Street. The fund oversees about $25 billion in assets under management, less than half the $60 billion it controlled in 2021. Despite shrinking in recent yeast, Ark Innovation Fund continues to attract billions of dollars from investors who are fond of Wood's investment strategy stock picking prowess. The hedge fund manager has relied on the thematic investment strategy to generate enormous returns in capital over a short period. Wood is best known for bets on companies with high earnings growth potential. While her investment strategy courts extreme levels of risks, including momentum, liquidity, valuation, and financial health, performance tends to be to the extreme on the highs of the lows. The fund had one of its best years after inception in 2017 as it posted an impressive 87.4% gain driven by a 1,300% run-up in Grayscale Bitcoin Trust. The run came as Bitcoin exploded to record highs of $20,000 a coin. However, it was in 2020 that Wood would make a name for herself on Wall Street as she posted a 152.5% gain with her flagship fund. Tesla, Inc. (NASDAQ:TSLA) is one of the stocks that have always propelled Woods to impressive gains in the market. She has always been bullish about the electric vehicle giant despite it facing valuation concerns. The high-growth stock accounts for nearly 8% of the portfolio manager exchange-traded funds. According to Woods, the automaker can reach $2,000 a share by 2027. Story continues Woods was one of the early investors to take advantage of the artificial intelligence boom. The super investor placed big bets on artificial intelligence plays, including Nvidia, while also insisting Tesla offered solid exposure to the disruptive innovation. While the flagship fund Ark Innovation ETF exited its position on NVIDIA Corporation (NASDAQ:NVDA) early, missing out on a blockbuster run, some of Woods's other ETFs still have positions in the ETF. Other companies that Wood expects to benefit from the AI boom include UiPath Inc. (NYSE:PATH), which is a robotic process automation software company, and Twilio Cloud Communication Company, which allows businesses to develop and integrate various communication channels. Wood's aggressive investment strategy has also seen her seek growth by investing in risky assets, including cryptocurrencies. The hedge fund manager has been bullish about Bitcoin even as other high-profile investors term it a scam. In January, Wood raised her firm's 2030 price of the flagship cryptocurrency to $1 million. According to Woods, Bitcoin has always been a perfect insurance policy for an uncertain economic world. In addition to investing in Bitcoin, she has also taken stakes in Coinbase Global, Inc. (NASDAQ:COIN), one of the largest cryptocurrency exchanges. She has also expressed her optimistic outlook on the impending approval of the Bitcoin exchange-traded fund by the US Securities and Exchange Commission. The portfolio manager expects the approval to enable individual and institutional investors to gain Bitcoin exposure. Through her flagship fund, Ark Innovation ETF, she invests heavily in disruptive technologies such as artificial intelligence, autonomous vehicles, and genomic medicine. These Cathie Wood Stocks Are On Sale Now Cathie Wood of ARK Investment Management Since its launch nine years ago, the flagship fund has generated significant returns and, in the process, bagged $310 million in fees. The fund charges an annual management fee of 0.75%, nearly double the average of other actively managed funds. Nevertheless, Woods's investment fund has generated poor results in recent years. The fund was on the receiving end last year as it plunged by nearly 70% as the overall stock market turned bearish on the Federal Reserve embarking on an aggressive interest rate hike. The losses were more than triple the 21% plunge recorded in 2021. Data shows that the flagship fund has lost $9.5 billion on risky bets in recent years. While the fund is up by about 25% year to date, a number of stocks have continued to pull the funds lower. The stocks have been a big disappointment, edging lower despite the overall market turning bullish. The double-digit percentage losses recorded by some of the stocks affirm that even market gurus are not immune to mistakes regarding stock picking. Our Methodology Cathie Wood's strategy of investing in small, often loss-making companies promising long returns has crumbled amid the high-interest rate environment and growing recession risks. High inflation levels and the Federal Reserve's hawkish policies have taken a significant toll on some of Woods's stock picks, depicted by the losses generated year to date. We have compiled some of the stocks that continue to take a toll on Wood's portfolio. The stocks are ranked chronologically based on the losses generated year to date. We have also reported the hedge fund view on each stock, which was obtained from Insider Monkey’s database of 910 leading hedge funds tracked as of the end of Q2 2023. These Cathie Wood Stocks Are On Sale Now 19. Spirit AeroSystems Holdings, Inc. (NYSE:SPR) Number of Hedge Fund Holders: 30 Year to Date Loss: 17% Spirit AeroSystems Holdings, Inc. (NYSE:SPR) is a company that designs, designs, and markets commercial aero structures worldwide. The company operates through three segments: commercial Defense, space, and Aftermarket. Spirit AeroSystems Holdings, Inc. (NYSE:SPR) is down by nearly 17% year to date, a situation compounded by the company announcing $105 million in losses on Boeing and Airbus aircraft production. Its long-term prospects also look bleak following the confirmation of a bleak cash flow for the rest of the year. Amid the concerns, Spirit AeroSystems Holdings, Inc. (NYSE:SPR) is currently rated as a ‘Hold’ on Wall Street with a $24.76 price target implying 47% upside potential. According to Insider Monkey’s second quarter database, Spirit AeroSystems Holdings, Inc. (NYSE:SPR) was part of 30 hedge fund portfolios. 18. Adyen N.V. (OTC:ADYEY) Number of Hedge Fund Holders: N/A Year to Date Loss: 29% Adyen N.V. (OTC:ADYEY) offers a payment platform that integrates a payment stack, including a gateway, risk management processing, and settlement services. The company also provides a back-end infrastructure for authorizing payments. The Dutch payment giant has been on the receiving end, its sentiments having taken a hit on weak earnings, raising concerns about its valuation. The company delivered earnings that missed expectations, a rare miss since it went public in 2018. The stock is currently rated as a Hold, having tanked by 29% year to date. 17. FARO Technologies, Inc. (NASDAQ:FARO) Number of Hedge Fund Holders: 21 Year to Date Loss: 41% FARO Technologies, Inc. (NASDAQ:FARO) designs develops, and manufactures software-driven three-dimensional measurement imaging and realization solutions. The company offers FaroArm, a portable articulated measurement arm, and CAM2 software programs. While the stock is down by 41% year to date, it is still rated as a Moderate Buy. According to Insider Monkey’s second-quarter database, 21 hedge funds were bullish on FARO Technologies, Inc. (NASDAQ:FARO), compared to 17 funds in the prior quarter. 16. AudioCodes Ltd. (NASDAQ:AUDC) Number of Hedge Fund Holders: 11 Year to Date Loss: 43% AudioCodes Ltd. (NASDAQ:AUDC) is a communication equipment company that provides advanced communications software products and productivity solutions. Its solutions are used to enable unified communications contacts centers and hosted business services. The stock has underperformed the overall market by the 43% year-to-date slide. In contrast, the S&P 500 has gained about 15%. Following the steep sell-off, the stock is rated as a Moderate Sell with an $10 price target implying 1.21% downside potential. According to Insider Monkey’s second quarter database, 11 hedge funds were bullish on AudioCodes Ltd. (NASDAQ:AUDC), compared to 9 funds in the earlier quarter. 15. Silicom Ltd. (NASDAQ:SILC) Number of Hedge Fund Holders: 9 Year to Date Loss: 44% Together with its subsidiaries, Silicom Ltd. (NASDAQ:SILC) designs, manufactures, and markets high-performance networking and data infrastructure solutions. Consequently, it offers server network interface cards and smart cards. The stock has disappointed Cathie Wood's portfolio, having tanked 44% year to date. As Insider Monkey’s database for Q2 reveals, Silicom Ltd. (NASDAQ:SILC) was owned by 9 hedge funds, no different from the previous quarter. 14. Xometry, Inc. (NASDAQ:XMTR) Number of Hedge Fund Holders: 16 Year to Date Loss: 50% Xometry, Inc. (NASDAQ:XMTR) operates an online marketplace that allows buyers to source manufactured parts and assemblies. It also provides computer numerical control manufacturing sheet metal forming, sheet cutting, and 3D printing. Xometry, Inc. (NASDAQ:XMTR) has underperformed the overall Wood's portfolio after warning early in the year of slower growth ahead. The company has struggled to make a mark amid its push to become a leader in 3D printing or computer-controlled manufacturing processes. The stock is down by 50% year to date and is rated as a Moderate Buy on Wall Street with a $24.71 price target implying a 49.31% upside potential. Insider Monkey’s Q2 database shows that Xometry, Inc. (NASDAQ:XMTR) was held by 16 hedge funds, unchanged from the previous quarter. 13. PyroGenesis Canada Inc. (NASDAQ:PYR) Number of Hedge Fund Holders: 1 Year to Date Loss: 52% PyroGenesis Canada Inc. (NASDAQ:PYR) is a company that designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, which enhances metal recovery from dross without hazardous by-products. PyroGenesis Canada Inc. (NASDAQ:PYR) hit 52-week lows as the provincial regulator triggered administrative proceedings against the company's CEO in connection to a settlement agreement in 2018 with Phoenix Haute Technology. The administrator is seeking penalties totalling $407,165. The stock is down by 52% year to date. According to Insider Monkey’s second-quarter database, 1 hedge fund was bullish on PyroGenesis Canada Inc. (NASDAQ:PYR), compared to 3 funds in the prior quarter. 12. Butterfly Network, Inc. (NYSE:BFLY) Number of Hedge Fund Holders: 15 Year to Date Loss: 54% Butterfly Network, Inc. (NYSE:BFLY) develops and commercializes ultrasound imaging solutions in the US. The company offers Butterfly IQ, a handheld and single-probe ultrasound system that connects with a smartphone, tablet, and computer system. Butterfly Network, Inc. (NYSE:BFLY) delivered disappointing second-quarter results with a net loss of $0.14 a share on revenues of $18.49 million, down from $19.22 million delivered a year ago. Wall Street rates the stock as a Moderate Buy even though it is down by 54% year to date. According to Insider Monkey’s second-quarter database, 15 hedge funds were bullish on Butterfly Network, Inc. (NYSE:BFLY), compared to 14 funds in the prior quarter. 11. JD.com, Inc. (NASDAQ:JD) Number of Hedge Fund Holders: 64 Year to Date Loss: 55% JD.com, Inc. (NASDAQ:JD) is a Chinese company that offers supply chain-based technologies and services. The company offers computers, communication, consumer electronics, home appliances, and general merchandise. It also offers online marketplace services for third-party merchants. JD.com, Inc. (NASDAQ:JD) has struggled to bounce back following regulators' crackdown on Chinese internet giants. In addition, the company has struggled in the market with disappointing earnings results and deteriorating economic conditions in Mainland China. Consequently, the stock has plunged 55% year to date even as analysts maintain a Moderate Buy on the stock with a $44.34 price target, implying 72.19% upside potential. According to Insider Monkey’s second-quarter database, 64 hedge funds were bullish on JD.com, Inc. (NASDAQ:JD), compared to 59 funds in the prior quarter. 10. Cerus Corporation (NASDAQ:CERS) Number of Hedge Fund Holders: 18 Year to Date Loss: 57% Cerus Corporation (NASDAQ:CERS) is a biomedical products company that develops and commercializes the INTERCEPT Blood System that enhances blood safety. The system is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Cerus Corporation (NASDAQ:CERS) delivered $38.9 million in product revenue in Q2, a decline from $41 million the prior year. Net loss soared to $13.3 million or $0.07 a share compared to $8.4 million or 0.05 a share delivered last year. Cerus Corporation (NASDAQ:CERS) is down by 57% year to date and is currently rated as a Moderate Buy with a $4 a share price target implying 153.16% upside potential. As of the end of the second quarter of 2023, 18 hedge funds had stakes in Cerus Corporation (NASDAQ:CERS). 9. PhenomeX Inc. (NASDAQ:CELL) Number of Hedge Fund Holders: 14 Year to Date Loss: 60% PhenomeX Inc. (NASDAQ:CELL) is a cell biology company that enables scientists to reveal insights into cell function and obtain the behavior of each cell. Its arsenal of tools enables unparalleled resolution and speed while looking to advance discoveries to improve the prevention and treatment of diseases. After underperforming for the better part of the year, the cell biology company has emerged as an acquisition target. Bruker has reached an agreement to acquire the company for a total equity value of $108 million. The stock is down by 60.8% year to date and is rated as a Hold with a $1 share price target implying 0.19% upside potential. Insider Monkey’s database of hedge funds shows that 14 hedge funds had stakes in PhenomeX Inc. (NASDAQ:CELL) during the second quarter of 2023. 8. Moderna, Inc. (NASDAQ:MRNA) Number of Hedge Fund Holders: 40 Year to Date Loss: 61% Moderna, Inc. (NASDAQ:MRNA) is a biotech company that uses messenger RNA to create treatments and vaccines for infections and rare and heart diseases. It also works on respiratory vaccines, including COVID-19 influenza and spikevax. Moderna, Inc. (NASDAQ:MRNA) prospects in the market have taken a significant hit due to a decline in demand for the COVID-19 vaccine, which has raked billions in revenues in previous years. Consequently, the stock has plunged 61% year to date. Amid the underperformance, Moderna is still rated as a Moderate Buy with a $123.23 price target, implying a 75.52% upside potential. Moderna, Inc. (NASDAQ:MRNA) was in 40 hedge fund portfolios, as per Insider Monkey’s database for Q2, the same as the prior quarter. 7. Prime Medicine, Inc. (NASDAQ:PRME) Number of Hedge Fund Holders: 12 Year to Date Loss: 64% Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company that delivers genetic therapies to address diseases by deploying gene editing technology. The company offers prime editors with Prime Editor Protein comprising of fusion between CAS protein and reverse transcriptase enzyme. Since going public last year, Prime Medicine, Inc. (NASDAQ:PRME) has underperformed the overall market. While the stock is rated as a Moderate Buy, it is down by 64% year to date. The consensus price target on the stock is $20.75, implying 211% upside potential. According to Insider Monkey’s second quarter database, 12 hedge funds were bullish on Prime Medicine, Inc. (NASDAQ:PRME), compared to 13 funds in the prior quarter. 6. Codexis, Inc. (NASDAQ:CDXS) Number of Hedge Fund Holders: 18 Year to Date Loss: 64% Codexis, Inc. (NASDAQ:CDXS) is a company that discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services that allow people to perform chemistry screening. After a poor run of form early in the year, the company sentiments received a boost after leading investment management firm BlackRock increased stakes in the company. The hedge fund acquired 882,588 shares for a 10.4% stake in Codexis, Inc. (NASDAQ:CDXS). Nevertheless, the stock is still down by 64% year to date and remains under immense pressure. Analysts on Wall Street rate the stock as a ‘Strong Buy’ with a $7.38 share price target, implying 272% upside potential. Insider Monkey’s database of 910 hedge funds shows that 18 hedge funds had stakes in Codexis, Inc. (NASDAQ:CDXS) at the end of Q2 2023. Click to continue reading and see 5 Cathie Wood Stocks that are on Sale Now. Suggested articles: 10 Best Home Security System Companies in 2023 10 Best ASX Stocks To Invest In 12 Best Automotive Stocks To Buy Now Disclosure: None. These Cathie Wood Stocks Are On Sale Now is originally published on Insider Monkey.
AUDC BFLY CDXS CELL CERS COIN FARO JD MRNA NVDA PATH PRME PYR SILC SPR TSLA XMTR | finance.yahoo | about 2 years ago | Neutral

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DBTX, CELL, CCF, AGENEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at th...
NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash plus one non-tradeable CVR worth up to $3.50 per share they own. Click here for more information: https://www.monteverdelaw.com/case/decibel-therapeutics-inc. It is free and there is no cost or obligation to you. PhenomeX Inc. (Nasdaq: CELL), relating to its proposed sale to Bruker Corp. Under the terms of the agreement, CELL shareholders will receive $1.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/phenomex-inc. It is free and there is no cost or obligation to you. Chase Corp. (NYSE: CCF), relating to its proposed sale to an affiliate of investment funds managed by KKR. Under the terms of the agreement, CCF shareholders are expected to receive $127.50 in cash per share they own. Click here for more information: https://monteverdelaw.com/case/chase-corp. It is free and there is no cost or obligation to you. AgeX Therapeutics, Inc. (NYSE: AGE), relating to its proposed merger with Serina Therapeutics, Inc. Under the terms of the agreement, AGE shareholders are expected to own approximately 25% of the combined company. Click here for more information: https://www.monteverdelaw.com/case/agex-therapeutics-inc. It is free and there is no cost or obligation to you. About Monteverde & Associates PC We are a national class action securities and consumer litigation law firm that has recovered millions of dollars for shareholders and is committed to protecting investors and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019 and a Super Lawyers Honoree in Securities Litigation in 2022-2023. He has also been selected by Martindale-Hubbell as a 2017-2023 Top Rated Lawyer. Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases. If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341. Contact: Juan E. Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4405 New York, NY 10118 United States of America jmonteverde@monteverdelaw.com Tel: (212) 971-1341 Attorney Advertising. (C) 2023 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
AGE CCF CELL DBTX | globenewswire | about 2 years ago | Neutral

Moore Kuehn Encourages CELL, CCF, IMNM, and KLR Investors to Contact Law FirmNEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increa...
NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies. Moore Kuehn is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: PhenomeX Inc. (NASDAQ: CELL) PhenomeX has agreed to merge with Bruker Corporation. Under the proposed transaction, PhenomeX shareholders will receive $1.00 in cash per share. Chase Corporation (NYSE: CCF) Chase Corporation has agreed to merge with an affiliate of investment funds managed by KKR. Under the proposed transaction, Chase shareholders will receive $127.50 in cash per share. Immunome, Inc. (NASDAQ: IMNM) Immunome has agreed to merge with Morphimmune. Under the proposed transaction, Immunome shareholders are expected to own 55% of the combined company. Kaleyra, Inc. (NYSE: KLR) Kaleyra has agreed to merge with Tata Communications. Under the proposed transaction, Kaleyra shareholders will receive $7.25 in cash per share. Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com. The consultation and case are free with no obligation to you. Moore Kuehn pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Moore Kuehn is a 5-star Google client-rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims. For additional information about Moore Kuehn, please visit http://www.moorekuehn.com/practice/new-york-securities-litigation/. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts: Moore Kuehn, PLLC Justin Kuehn, Esq. 30 Wall Street, 8th Floor New York, New York 10005 jkuehn@moorekuehn.com (212) 709-8245
CCF CELL IMNM KLR | globenewswire | about 2 years ago | Neutral

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CCF, VRTV, CELLNEW YORK, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chase Corporation (NYSE: CCF)’s sale to an ...

CCF CELL VRTV | globenewswire | about 2 years ago | Neutral

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – HCCI, CEQP, CELL, CTGNEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at t...
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: Heritage-Crystal Clean, Inc. (Nasdaq: HCCI), relating to its proposed sale to an affiliate of J.F. Lehman & Co. Under the terms of the agreement, HCCI shareholders are expected to receive $45.50 in cash per share they own. Click here for more information: https://monteverdelaw.com/case/heritage-crystal-clean-inc. It is free and there is no cost or obligation to you. Crestwood Equity Partners LP (NYSE: CEQP), relating to its proposed sale to Energy Transfer LP. Under the terms of the agreement, CEQP shareholders will receive 2.07 shares of Energy Transfer per share they own. Click here for more information: https://www.monteverdelaw.com/case/crestwood-equity-partners-lp. It is free and there is no cost or obligation to you. PhenomeX Inc. (Nasdaq: CELL), relating to its proposed sale to Bruker Corp. Under the terms of the agreement, CELL shareholders will receive $1.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/phenomex-inc. It is free and there is no cost or obligation to you. Computer Task Group, Inc. (Nasdaq: CTG), relating to its proposed sale to Cegeka Groep NV. Under the terms of the agreement, CTG shareholders will receive $10.50 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/computer-task-group-inc. It is free and there is no cost or obligation to you. About Monteverde & Associates PC We are a national class action securities and consumer litigation law firm that has recovered millions of dollars for shareholders and is committed to protecting investors and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019 and a Super Lawyers Honoree in Securities Litigation in 2022-2023. He has also been selected by Martindale-Hubbell as a 2017-2023 Top Rated Lawyer. Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases. If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341. Contact: Juan E. Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4405 New York, NY 10118 United States of America jmonteverde@monteverdelaw.com Tel: (212) 971-1341 Attorney Advertising. (C) 2023 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
CELL CEQP CTG HCCI | globenewswire | about 2 years ago | Neutral

PhenomeX Inc. Announces Commencement of Cash Tender Offer by BrukerEMERYVILLE, Calif., Sept. 5, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL) today announced that Bruker Corporation (Nasdaq: BRKR) has commenced, through its wholly owned subsidiary, Bird Mergersub Corporation, a cash tender offer to purchase all outstanding shares of common stock of PhenomeX for...
EMERYVILLE, Calif., Sept. 5, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL) today announced that Bruker Corporation (Nasdaq: BRKR) has commenced, through its wholly owned subsidiary, Bird Mergersub Corporation, a cash tender offer to purchase all outstanding shares of common stock of PhenomeX for $1.00 per share. The tender offer is being made pursuant to the previously announced merger agreement between PhenomeX and Bruker entered into on August 17, 2023. Following the successful closing of the tender offer, Bird Mergersub Corporation will be merged into PhenomeX with PhenomeX becoming a wholly owned subsidiary of Bruker. PhenomeX (Nasdaq: CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX) On August 31, 2023, Bruker filed with the U.S. Securities and Exchange Commission (the "SEC") a tender offer statement on Schedule TO that provides the terms of the tender offer. Additionally, PhenomeX has filed with the SEC a solicitation/recommendation statement on Schedule 14D-9 that includes the recommendation of the PhenomeX board of directors that PhenomeX stockholders accept the tender offer and tender their shares. The tender offer will expire one minute after 11:59 p.m., Eastern Time, on September 28, 2023, unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC. The closing of the tender offer is subject to certain conditions, including the tender of shares representing at least a majority of the total number of PhenomeX's outstanding shares. PhenomeX has no affiliation with Phenomenex, Inc., and Phenomenex, Inc. has no involvement in the transaction with Bruker. PhenomeX will be changing its name. All inquiries regarding Phenomenex, Inc. and/or its products should be directed to info@phenomenex.com. About PhenomeX PhenomeX is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. Our unique suite of proven high-throughput tools and services offer unparalleled resolution and speed, accelerating the insights that are key to advancing discoveries that can profoundly improve the prevention and treatment of disease. Our award-winning platforms are used by researchers across the globe, including those at the top 15 global pharmaceutical companies and approximately 85% of leading U.S. comprehensive cancer centers. Story continues About Bruker Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life-science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial research, semiconductor metrology and cleantech applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com. Additional Information about the Tender Offer and Where to Find It This communication is neither an offer to purchase nor a solicitation of an offer to sell securities. Bruker and its acquisition subsidiary have filed a tender offer statement on Schedule TO with the SEC, and PhenomeX has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC. Investors and PhenomeX security holders are strongly advised to read the tender offer statement (including the offer to purchase, letter of transmittal and related tender offer documents) that have been filed by Bruker and its acquisition subsidiary with the SEC and the related solicitation/recommendation statement on Schedule 14D-9 that has been filed by PhenomeX with the SEC, in their entirety, because they contain important information, including the terms and conditions of the offer. These documents are available at no charge on the SEC's website at www.sec.gov or from the information agent that will be named in the tender offer materials. In addition, a copy of the tender offer statement and other related documents filed with or furnished to the SEC by Bruker or its acquisition subsidiary may be obtained free of charge on Bruker's website at ir.bruker.com, and a copy of the solicitation/recommendation statement and other related documents filed with or furnished to the SEC may be obtained free of charge on PhenomeX's website at investors.phenomex.com. Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/phenomex-inc-announces-commencement-of-cash-tender-offer-by-bruker-301918180.html SOURCE PhenomeX
BRKR CELL | finance.yahoo | about 2 years ago | Neutral

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DBTX, CELL, ESTE, CPRINEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the...
NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash plus one non-tradeable CVR worth up to $3.50 per share they own. Click here for more information: https://www.monteverdelaw.com/case/decibel-therapeutics-inc. It is free and there is no cost or obligation to you. PhenomeX Inc. (Nasdaq: CELL), relating to its proposed sale to Bruker Corp. Under the terms of the agreement, CELL shareholders will receive $1.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/phenomex-inc. It is free and there is no cost or obligation to you. Earthstone Energy, Inc. (NYSE: ESTE), relating to its proposed merger with Permian Resources Corp. Under the terms of the agreement, ESTE shareholders will receive 1.446 shares of Permian per share they own. Click here for more information: https://www.monteverdelaw.com/case/earthstone-energy-inc. It is free and there is no cost or obligation to you. Capri Holdings Ltd. (NYSE: CPRI), relating to its proposed sale to Tapestry, Inc. Under the terms of the agreement, CPRI shareholders will receive $27.05 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/capri-holdings-ltd. It is free and there is no cost or obligation to you. About Monteverde & Associates PC We are a national class action securities and consumer litigation law firm that has recovered millions of dollars for shareholders and is committed to protecting investors and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019 and a Super Lawyers Honoree in Securities Litigation in 2022-2023. He has also been selected by Martindale-Hubbell as a 2017-2023 Top Rated Lawyer. Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases. If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341. Contact: Juan E. Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4405 New York, NY 10118 United States of America jmonteverde@monteverdelaw.com Tel: (212) 971-1341 Attorney Advertising. (C) 2023 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
CELL CPRI DBTX ESTE | globenewswire | about 2 years ago | Neutral

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CEQP, CELL, DINO, PRTKNEW YORK, Aug. 27, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Crestwood Equity Partners LP (NYSE: CEQP)’s ...
NEW YORK, Aug. 27, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Crestwood Equity Partners LP (NYSE: CEQP)’s sale to Energy Transfer LP for 2.07 Energy Transfer common units for each Crestwood common unit. Upon closing, Crestwood common unitholders are expected to own approximately 6.5% of Energy Transfer’s outstanding common units. If you are a Crestwood shareholder, click here to learn more about your rights and options. PhenomeX Inc. (NASDAQ: CELL)’s sale to Bruker Corporation for $1.00 per share. If you are a PhenomeX shareholder, click here to learn more about your rights and options. HF Sinclair Corporation (NYSE: DINO)’s merger with Holly Energy Partners, L.P. Under the terms of the agreement, each Holly Energy common unit holder would receive 0.315 shares of HF Sinclair common stock and $4.00 in cash, without interest, for each publicly held Holly Energy common unit. If you are a HF Sinclair shareholder, click here to learn more about your rights and options. Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK)’s sale to Gurnet Point Capital and Novo Holdings A/S. Under the terms of the agreement, Paratek shareholders will receive $2.15 per share in cash, plus a Contingent Value Right of $0.85 per share payable upon the achievement of $320 million in U.S. NUZYRA net sales (excluding certain permitted deductions, payments under Paratek’s contract with ASPR-BARDA, certain government payments and certain royalty revenue) in any calendar year ending on or prior to December 31, 2026. If you are a Paratek shareholder, click here to learn more about your rights and options. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Halper Sadeh LLC Daniel Sadeh, Esq. Zachary Halper, Esq. (212) 763-0060 sadeh@halpersadeh.com zhalper@halpersadeh.com https://www.halpersadeh.com
CELL CEQP DINO PRTK | globenewswire | about 2 years ago | Neutral

Lifshitz Law PLLC Announces Investigations of TMBR, PR, ESTE, and CELLNEW YORK, Aug. 26, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. (NYSE: TMBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of TMBR to LEO Pharma A/S for (i) an initial upfront consideration of $14 million and (ii) up to...
NEW YORK, Aug. 26, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. (NYSE: TMBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of TMBR to LEO Pharma A/S for (i) an initial upfront consideration of $14 million and (ii) up to an additional $22 million in contingent value rights payable upon achievement of specific milestones for TMB-001. If you are a TIMBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com. Permian Resources Corporation (NYSE: PR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of PR and Earthstone Energy, Inc. Under the terms of the proposed transactions, each share of Earthstone Energy, Inc. will be exchanged for a fixed ratio of 1.446 shares of PR common stock. If you are a PR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com. Earthstone Energy, Inc. (NYSE: ESTE) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of ESTE and Permian Resources Corporation. Under the terms of the proposed transactions, each share of ESTE will be exchanged for a fixed ratio of 1.446 shares of Permian Resources Corporation common stock. If you are an ESTE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com. PhenomeX Inc. (NASDAQ: CELL) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CELL to Bruker Corporation for $1.00 per share in cash for each share of CELL common stock owned. If you are a CELL investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com. ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact: Joshua M. Lifshitz, Esq. Lifshitz Law PLLC Phone: 516-493-9780 Facsimile: 516-280-7376 Email: info@lifshitzlaw.com
CELL ESTE PR TMBR | globenewswire | about 2 years ago | Neutral

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – CELL, DBTX, CPRI, ESTENEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the...
NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: PhenomeX Inc. (Nasdaq: CELL), relating to its proposed sale to Bruker Corp. Under the terms of the agreement, CELL shareholders will receive $1.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/phenomex-inc. It is free and there is no cost or obligation to you. Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash plus one non-tradeable CVR worth up to $3.50 per share they own. Click here for more information: https://www.monteverdelaw.com/case/decibel-therapeutics-inc. It is free and there is no cost or obligation to you. Capri Holdings Ltd. (NYSE: CPRI), relating to its proposed sale to Tapestry, Inc. Under the terms of the agreement, CPRI shareholders will receive $27.05 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/capri-holdings-ltd. It is free and there is no cost or obligation to you. Earthstone Energy, Inc. (NYSE: ESTE), relating to its proposed merger with Permian Resources Corp. Under the terms of the agreement, ESTE shareholders will receive 1.446 shares of Permian per share they own. Click here for more information: https://www.monteverdelaw.com/case/earthstone-energy-inc. It is free and there is no cost or obligation to you. About Monteverde & Associates PC We are a national class action securities and consumer litigation law firm that has recovered millions of dollars for shareholders and is committed to protecting investors and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019 and a Super Lawyers Honoree in Securities Litigation in 2022-2023. He has also been selected by Martindale-Hubbell as a 2017-2023 Top Rated Lawyer. Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases. If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341. Contact: Juan E. Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4405 New York, NY 10118 United States of America jmonteverde@monteverdelaw.com Tel: (212) 971-1341 Attorney Advertising. (C) 2023 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
CELL CPRI DBTX ESTE | globenewswire | about 2 years ago | Neutral

Profile

PhenomeX Inc. (CELL)

PhenomeX Inc. operates as a functional cell biology company. The company enables scientists to reveal insights on cell function and obtain behavior of each cell. Its suite of tools and services offer unparalleled resolution and speed, accelerating the insights for advancing discoveries that can profoundly improve the prevention and treatment of disease. The company's platforms are used by researchers worldwide, including pharmaceutical companies and comprehensive cancer centers. PhenomeX Inc. is headquartered in Emeryville, California. As of September 29, 2023, PhenomeX Inc. operates as a subsidiary of Bruker Corporation.

Exchange: NASDAQ

IPO Date: 7/17/2020

Sector: Healthcare

Industry: Biotechnology

Employees: 285

Address:

Quarterly Yearly

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	06/30/2023	03/31/2023	12/31/2022	09/30/2022	06/30/2022	03/31/2022	Totals
	06/30/2023	03/31/2023	12/31/2022	09/30/2022	06/30/2022	03/31/2022	Totals
Assets	178.33K	300.56K	226.09K	234.88K	248.71K	265.86K	1.45M
Current Assets	94.79K	131.64K	176.95K	180.96K	192.47K	208.36K	985.17K
Cash And Short Term Investments	-	51.61K	-	-	-	-	51.61K
Net Receivables	14.38K	25.12K	18.53K	20.25K	13.81K	17.72K	109.82K
Inventory	41.45K	45.54K	18.86K	15.71K	15.66K	15.66K	152.89K
Other Current Assets	7.99K	9.38K	6.78K	3.48K	3.23K	3.54K	34.41K
Non Current Assets	83.55K	168.92K	49.14K	53.92K	56.24K	57.49K	469.26K
Non Currrent Assets Other	2.11K	72.31K	1.97K	2.10K	2.40K	2.25K	83.14K
Liabilities	67.05K	142.82K	84.04K	76.70K	74.29K	72.66K	517.56K
Current Liabilities	42.23K	47.44K	45.49K	34.38K	29.14K	27.71K	226.39K
Accounts Payable	18.63K	17.05K	10.09K	7.92K	8.50K	8.02K	70.21K
Short Long Term Debt	-	-	4.97K	2.48K	-	-	7.45K
Other Current Liabilities	1.64K	19.64K	1.62K	1.42K	660	641	25.63K
Non Current Liabilities	24.83K	95.38K	38.55K	42.32K	45.15K	44.95K	291.17K
Stockholder Equity	111.28K	157.74K	142.06K	158.18K	174.42K	193.20K	936.88K
Liabilities And Stockholders Equity	-	300.56K	-	-	-	-	300.56K
Totals		688.25K	1.59M	825.14K	834.73K	864.67K	918.07K	5.72M

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2022	12/31/2021	12/31/2020	12/31/2019	Totals
	12/31/2022	12/31/2021	12/31/2020	12/31/2019	Totals
Assets	226.09K	287.25K	299.66K	131.01K	944.01K
Current Assets	176.95K	230.57K	265.57K	105.35K	778.44K
Net Receivables	18.53K	25.94K	12.94K	9.33K	66.75K
Inventory	18.86K	14.55K	11.05K	7.18K	51.64K
Other Current Assets	6.78K	11.98K	8.18K	1.95K	28.89K
Non Current Assets	49.14K	56.68K	34.09K	25.66K	165.58K
Non Currrent Assets Other	1.97K	2.63K	2.83K	1.41K	8.83K
Liabilities	84.04K	79.04K	54.88K	47.23K	265.18K
Current Liabilities	45.49K	32.75K	28.97K	24.92K	132.13K
Accounts Payable	10.09K	8.20K	3.49K	3.24K	25.02K
Short Long Term Debt	4.97K	-	11.59K	5.76K	22.32K
Other Current Liabilities	1.62K	1.14K	463	963	4.18K
Non Current Liabilities	38.55K	46.29K	25.91K	22.31K	133.05K
Stockholder Equity	142.06K	208.22K	244.78K	83.78K	678.84K
Totals		825.14K	1.01M	1.00M	470.09K	3.30M

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	Totals
	Totals
Totals		-

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	Totals
	Totals
Totals		-

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	06/30/2023	03/31/2023	12/31/2022	09/30/2022	06/30/2022	03/31/2022	Totals
	06/30/2023	03/31/2023	12/31/2022	09/30/2022	06/30/2022	03/31/2022	Totals
Cash From Operating Activities	-19.86K	-19.55K	-10.04K	-16.91K	-10.52K	-10.07K	-86.96K
Net Income	-50.24K	-23.42K	-29.30K	-21.57K	-25.75K	-21.43K	-171.70K
Depreciation	5.33K	2.95K	3.22K	2.94K	3.29K	2.68K	20.40K
Extraordinary Items	-	-	-	-	-	-	-
Change To Inventory	-5.08K	964	-564	149	-222	-1.32K	-6.07K
Capital Expenditures	-43	-414	-344	-974	-2.38K	-4.38K	-8.53K
Cash From Financing Activities	-70.73K	48.99K	8.13K	176	354	1.02K	-12.06K
Totals		-140.65K	9.53K	-28.90K	-36.19K	-35.23K	-33.49K	-264.93K

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	12/31/2022	12/31/2021	12/31/2020	12/31/2019	Totals
	12/31/2022	12/31/2021	12/31/2020	12/31/2019	Totals
Cash From Operating Activities	-47.54K	-53.13K	-35.85K	-10.53K	-147.05K
Net Income	-98.04K	-71.72K	-41.58K	-18.30K	-229.65K
Depreciation	12.12K	7.92K	6.79K	6.51K	33.36K
Extraordinary Items	-	-	-	-	-
Change To Inventory	-1.95K	-6.63K	-4.23K	-4.02K	-16.83K
Capital Expenditures	-8.08K	-15.82K	-3.29K	-8.42K	-35.61K
Cash From Financing Activities	9.68K	13.64K	191.52K	1.02K	215.86K
Totals		-133.81K	-125.75K	113.36K	-33.74K	-179.94K

Profile

Free Stocks

Company

Features

Contact Us